Why the study?
The exact impact of cilostazol combined with P2Y12 receptor inhibitors on platelet function and clinical benefits in aspirin-intolerant patients undergoing percutaneous coronary stent implantation was unknown.
Does cilostazol combined with P2Y12 receptor inhibitors prevent MACCE compared to aspirin combined with P2Y12 receptor inhibitors in aspirin-intolerant patients undergoing percutaneous coronary stent implantation?
Does cilostazol combined with P2Y12 receptor inhibitors prevent MACCE compared to aspirin combined with P2Y12 receptor inhibitors in aspirin-intolerant patients undergoing percutaneous coronary stent implantation?
Cilostazol combined with a P2Y12 inhibitor provides a safe and effective alternative to aspirin-based dual antiplatelet therapy for aspirin-intolerant patients undergoing percutaneous coronary intervention.
Answers are grounded in this paper and cite their sources.
May support P2Y12 monotherapy in aspirin-intolerant PCI patients; leaves open need for RCTs to confirm safety and efficacy.
BACKGROUND: receptor inhibitor has been used as a substitute regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation on a small scale. Its exact impact on platelet functions and clinical benefits of aspirin-intolerant patients is unknown. HYPOTHESIS: receptor inhibitors could be used as a substitute antiplatelet regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation. METHODS: receptor inhibitors). Platelet PAC-1, CD62p, and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) were detected by flow cytometry. The primary endpoints were major adverse cardiovascular and cerebrovascular events (MACCE) including all-cause death, acute myocardial infarction, emerging arrhythmia, nonfatal stroke, and heart failure. The secondary endpoints were the Bleeding Academic Research Consortium (BARC) bleeding events. RESULTS: One hundred and fifty-four aspirin-intolerant percutaneous coronary stent implantation patients and 154 matched aspirin-tolerant patients from a total of 2059 percutaneous coronary stent implantation patients were enrolled. The relative activation level of PAC-1, CD62p, and platelet reaction index reflected by the VASP-P test were similar in the two groups (p > .05). After 12 months of follow-up, the incidence of all-cause death was 1.9% in the cilostazol group and 1.3% in the aspirin group (risk ratio [RR], 1.500; 95% confidence interval [CI], 0.254-8.852; p = 1.000); the incidence of acute myocardial infarction was 0.6% in the cilostazol group and 1.3% in the aspirin group (RR, 0.500; 95% CI, 0.046-5.457; p = 1.000). No significant difference was seen in other MACCE events, or in any types of BARC bleeding events. CONCLUSIONS: inhibitors was not inferior to aspirin-based standard therapy and could be used as a reasonable substitute antiplatelet regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation, but again with limitations, which required a larger sample and longer follow-up to confirm its efficacy.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: